Athersys Company Description

Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area.

Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions.

The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to Chapter 7.

It had filed for Chapter 11 bankruptcy along with its affiliates on January 5, 2024.

Athersys, Inc.

Country	United States
Founded	1995
Industry	Biotechnology
Sector	Healthcare
Employees	24

Contact Details

Address: 3201 Carnegie Avenue Cleveland, Ohio 44115-2634 United States
Phone	216 431 9900
Website	athersys.com

Stock Details

Ticker Symbol	ATHXQ
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Z. Kasey Rosado	Interim Chief Financial Officer and Director
Dr. Senthil Ranganathan Ph.D.	Vice President of Technical Operations
David Russ M.B.A.	Vice President of Supply Chain, Finance and Administration
Dr. Manal Morsy M.B.A., M.D., PH.D.	Executive Vice President and Head of Global Regulatory Affairs
Dr. Robert Mays Ph.D.	Executive Vice President, Head of Regenerative Medicine and Neuroscience Programs
Rakesh Ramachandran MS	Head of Information Technology and Communications and Vice President
Dr. Sarah Busch Ph.D.	Vice President of Regenerative Medicine and Head of Business Development
Ellen Gurley	Manager of Corporate Communications and Investor Relations